Tag: FDA warning
-
Ukoniq Drug Recall in April 2022 Comes Soon After FDA Warning About Increased Risk of Death in February 2022
This "New" Lymphoma Drug Had Only Been on the Market Since February 2021, When Ukoniq Received FDA Accelerated Approval (Posted by Tom Lamb at Drug Injury Watch) In February 2022 we wrote about this Drug…
-
Belviq Cancer Risk Warning Alert Issued To Patients And Doctors In January 2020 FDA Drug Safety Communication
Recent Clinical Trial Findings Suggest Use Of The Weight-Loss Medicine Belviq Increased Risk Of Cancers (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: "FDA requests the withdrawal of the weight-loss drug Belviq, Belviq…
-
Benicar (Olmesartan) Associated With Sprue-Like Enteropathy, Which Is A Chronic / Severe Diarrhea Condition That Can Be Misdiagnosed As Celiac Disease
This Diarrhea With Weight Loss Is Also A Side Effect Of Benicar HCT, Azor, And Tribenzor — Other Blood Pressure Medicines Containing Olmesartan (Posted by Tom Lamb at DrugInjuryWatch.com)An association between the serious side…
-
Like Depakote, Stavzor Can Cause Liver Failure, Usually During First 6 Months; Children Under Age 2 Are At A Higher Risk, As Are Patients with Mitochondrial Disease
Black-Box Warning Added To Stavzor Label Announced By FDA In March 2014, Almost Full Year After Similar Label Change For Depakote Hepatotoxicity (Posted by Tom Lamb at DrugInjuryWatch.com)Stavzor, a lesser known valproic acid medication…
-
Pfizer’s Lipitor Statin Drug For Treatment Of High Cholesterol Linked To An Increased Risk Of Type-2 Diabetes In Some Older And Post-Menopausal Women
February 2012 FDA Drug Safety Warning About Lipitor Label Change Concerning New-Onset Diabetes Mellitus (DM) Has Gone Largely Unnoticed To Date (Posted by Tom Lamb at DrugInjuryWatch.com)Statins are a class of prescription drugs used…
-
Emerging Drug Safety Issue: Possible Increased Risk Of Pancreatic Cancer With Byetta, Januvia, And Victoza — Little Is Known About Long-Term Effects
As “Pancreatitis Is On The Pathway Toward Pancreatic Cancer”, Medical Studies Needed To Determine If GLP-1 Diabetes Medications Linked To Cancers Or Malignancies Involving Pancreas (Posted by Tom Lamb at DrugInjuryWatch.com)______________________________________________________________________________ UPDATE: “Cancer of The Pancreas:…
-
Increased Risk Of Bladder Cancer Warning Added To Actos Label By Takeda Announced In August 2011
European Drug Regulator EMA Recommended New Actos Contra-Indications And Warnings In July 2011 (Posted by Tom Lamb at DrugInjuryWatch.com) _____________________________________________________________________ UPDATE: "European Medicines Agency clarifies opinion on pioglitazone and the risk of bladder cancer" …
-
Actos-Related Bladder Cancer: June 2011 Review Of Regulatory Actions And Safety Warnings
FDA And Health Canada Warn About Increased Risk, While France And Germany Suspend Actos Sales (Posted by Tom Lamb at DrugInjuryWatch.com) ______________________________________________________________________________ UPDATE: "FDA Drug Safety Communication: Updated drug labels for pioglitazone-containing medicines" (8/4/11)…
-
June 2011 FDA Warning About 80 mg Dose Of Zocor, Simvastatin, And Vytorin Cholesterol Medications
Highest Simvastatin Dosage Linked To Potentially Fatal Rhabdomyolysis Muscle Injury And Kidney Failure (Posted by Tom Lamb at DrugInjuryWatch.com) On June 8, 2011 the FDA announced new dosing restrictions for Zocor and other prescription drug…
-
Topamax During Pregnancy Increases Risk Of Cleft Lip And/Or Cleft Palate Birth Defects
Oral Clefts In Babies Are 20 Times More Likely With Women Who Used Topamax (topiramate) After Getting Pregnant (Posted by Tom Lamb at DrugInjuryWatch.com) In early March 2011 the FDA announced that the prescribing information…